Dysport
Spasticity
IpsenPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Spasticity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nabiximols Jazz Pharmaceuticals | Phase 4 | BBB |
Arbaclofen RVL Pharmaceuticals, Inc. | Phase 3 | BB |
Baclofen RVL Pharmaceuticals, Inc. | Phase 3 | BB |
gw-1000-02 Jazz Pharmaceuticals | Phase 3 | BB |
Xeomin® Daewoong Pharmaceutical Co. LTD. | Phase 3 | BB |
View all 13 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →